Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor

Hakyoung Kim, Won Park, Young Seok Kim, Yeon Joo Kim, Hakyoung Kim, Won Park, Young Seok Kim, Yeon Joo Kim

Abstract

Objectives: There is no consensus on whether giving adjuvant concurrent chemoradiotherapy (CCRT) is more effective than adjuvant radiotherapy (RT) alone in patients with early stage cervical cancer and intermediate-risk factor(s). The purpose of this study was to evaluate survival difference according to adjuvant treatment in the intermediate-risk group.

Methods: From 2000 to 2014, the medical records of patients with stage IB-IIA cervical cancer and a history of radical hysterectomy with pelvic lymph node dissection, followed by pelvic RT at a dose ≥40 Gy were retrospectively reviewed. Among these, 316 patients with one or more intermediate-risk factor(s) and no high-risk factors were included. The criteria defined the intermediate-risk group as those patients with any of the following intermediate-risk factors: lymphovascular space involvement, over one-half stromal invasion, or tumor size ≥4 cm.

Results: The median follow-up duration was 70 months (range: 3-203 months). According to adjuvant treatment (adjuvant RT alone vs. adjuvant CCRT), the 5-year recurrence-free survival rates (90.8% vs. 88.9%, p=0.631) and 5-year overall survival rates (95.9% vs. 91.0%, p=0.287) did not show a significant difference in patients with any of the intermediate-risk factors. In multivariate analysis, a distinct survival difference according to adjuvant treatment was not found regardless of the number of risk factors.

Conclusion: The present study showed that giving RT together with chemotherapy is not more effective than RT alone for stage IB-IIA cervical cancer patients with intermediate-risk factor(s).

Trial registration: ClinicalTrials.gov Identifier: NCT01101451.

Keywords: Adjuvant Radiotherapy; Cervical Cancer; Risk Factor; Survival Analysis.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

Figures

Fig. 1. RFS curves according to adjuvant…
Fig. 1. RFS curves according to adjuvant treatment.
CCRT, concurrent chemoradiotherapy; RFS, recurrence-free survival; RT, radiotherapy.
Fig. 2. OS curves according to adjuvant…
Fig. 2. OS curves according to adjuvant treatment.
CCRT, concurrent chemoradiotherapy; OS, overall survival; RT, radiotherapy.

References

    1. Lahousen M, Haas J, Pickel H, Hackl A, Kurz C, Ogris H, et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: a randomized, prospective, multicenter trial. Gynecol Oncol. 1999;73:196–201.
    1. Rose PG. Advances in the management of cervical cancer. J Reprod Med. 2000;45:971–978.
    1. Rotman M, John M, Boyce J. Prognostic factors in cervical carcinoma: implications in staging and management. Cancer. 1981;48:560–567.
    1. Inoue T. Prognostic significance of the depth of invasion relating to nodal metastases, parametrial extension, and cell types. A study of 628 cases with stage IB, IIA, and IIB cervical carcinoma. Cancer. 1984;54:3035–3042.
    1. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352–357.
    1. Sevin BU, Lu Y, Bloch DA, Nadji M, Koechli OR, Averette HE. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. Cancer. 1996;78:1438–1446.
    1. Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol. 2004;93:458–464.
    1. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol. 2005;99:106–112.
    1. Zaino RJ, Ward S, Delgado G, Bundy B, Gore H, Fetter G, et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Cancer. 1992;69:1750–1758.
    1. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177–183.
    1. Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–176.
    1. Sartori E, Tisi G, Chiudinelli F, La Face B, Franzini R, Pecorelli S. Early stage cervical cancer: adjuvant treatment in negative lymph node cases. Gynecol Oncol. 2007;107:S170–4.
    1. Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF., Jr Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. Gynecol Oncol. 1997;66:31–35.
    1. Lai CH, Hong JH, Hsueh S, Ng KK, Chang TC, Tseng CJ, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer. 1999;85:1537–1546.
    1. Yang K, Park W, Huh SJ, Bae DS, Kim BG, Lee JW. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiat Oncol J. 2017;35:39–47.
    1. Ryu SY, Park SI, Nam BH, Cho CK, Kim K, Kim BJ, et al. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors? Int J Radiat Oncol Biol Phys. 2011;79:794–799.
    1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143.
    1. Song S, Song C, Kim HJ, Wu HG, Kim JH, Park NH, et al. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy. Gynecol Oncol. 2012;124:63–67.
    1. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Yoshioka Y, Sasano T, et al. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer. 2013;23:567–575.
    1. Qin AQ, Liang ZG, Ye JX, Li J, Wang JL, Chen CX, et al. Significant efficacy of additional concurrent chemotherapy with radiotherapy for postoperative cervical cancer with risk factors: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2016;17:3945–3951.
    1. Matsuo K, Shimada M, Yokota H, Satoh T, Katabuchi H, Kodama S, et al. Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. Oncotarget. 2017;8:106866–106875.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever